Human cells and tissues: current good tissue practice

FDA’s tissue overview describes human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient as HCT/Ps: human cells, tissues, and cellular and tissue-based products. The term identifies a regulatory subject. It does not describe a medical outcome or establish a therapeutic claim.

Part 1271 contains donor-eligibility and current good tissue practice provisions. Its scope also distinguishes different regulatory pathways and the possible application of other requirements. A company’s assessment therefore needs the actual criteria and activities involved. A general HCT/P description cannot establish that only one set of requirements applies to a particular operation.

Part 1271 requires an establishment performing a manufacturing step to maintain a quality programme appropriate to its HCT/Ps and the steps performed. The rule describes a programme intended to prevent the introduction, transmission or spread of communicable disease. It includes procedures, information review, corrective action, personnel training, monitoring and investigation of deviations relating to the applicable core requirements.

A practical programme map can link each step to a responsible function and the evidence it needs. Include the information that arrives from another establishment and the information that must leave with the material. A handoff is controlled when the receiving team can understand the identity, status and relevant history. The quality-system page explains how responsibilities, evidence and management review support this kind of connected work.

FDA’s tissue overview describes donor screening and testing, written procedures and records among the regulatory requirements. Part 1271 places donor-eligibility determinations in a distinct part of the framework while connecting them with the wider tissue-practice controls. Manufacturing staff need a clear understanding of status and the information required for the step they perform.

A practical records check follows that status into processing and distribution review. If information is incomplete or inconsistent, the approved process should establish how the issue is handled. An unexplained assumption about donor status can propagate through later records. Clear identification and controlled handoffs make the issue visible while the relevant evidence can still be reviewed. The aim is a complete account of the manufacturing decisions, without turning that account into advice about an individual recipient.

Part 1271 requires personnel to have the education, experience and training needed for competent performance and to perform only activities for which they are qualified and authorised. It also requires training and retraining as necessary. Procedures need appropriate review and approval and must be available where the related operations occur.

A practical training check can ask whether staff can use the approved procedure and identify when the task needs escalation. Procedure availability matters at the moment of work, particularly when a revision changes a decision or record entry. If an instruction is adopted from elsewhere, the regulation requires verification that it meets the applicable requirements and fits the operation. Familiar wording alone does not demonstrate that fit.

Part 1271 addresses facilities suitable to prevent contamination and mix-ups, cleaning and sanitation, equipment design, maintenance and calibration where appropriate. It also addresses processing controls and supplies and reagents. These subjects interact. Equipment that is difficult to maintain may affect the control described in a procedure; an unclear area boundary may complicate material handling.

A practical review follows the physical operation rather than checking equipment records alone. Consider how cleaning status is communicated, how staff identify material at a handoff and how an unusual equipment condition reaches quality review. The regulation requires process changes to be verified or validated as applicable, approved before implementation and communicated to the relevant personnel. Reviewing connected controls helps the team understand whether a change creates a problem elsewhere.

Part 1271 requires records concurrently with the relevant steps. The records must be accurate, legible and detailed enough to provide the history of the work and relate it to the particular HCT/P. It also describes a records-management system that supports retrieval, review before distribution and later investigation when needed.

The rule’s tracking provisions connect the donor with the consignee or final disposition and back again. A practical tracking exercise can test whether the identifiers and records support that connection across establishments. A new identifier should not break the relationship with earlier information. The documentation page explains why record quality depends on the evidence trail, including the source information behind a summary or transferred record.

Part 1271 describes review of manufacturing and tracking records before an HCT/P is made available for distribution, with verification and documentation that the release criteria have been met. It also addresses receipt, quarantine, packaging and shipping. The distribution decision therefore needs a supported basis, not merely an indication that processing is finished.

A useful internal review distinguishes completion of a processing step from completion of all required assessments. Follow any unresolved information into its disposition, and preserve the reason for each decision. FDA’s CGTP guidance page identifies recommendations concerning the tissue-practice and additional requirements. Use the applicable regulation and approved company procedures to assess the actual activity. The quality programme then connects those requirements with the evidence from daily work.